Form 4 for REGN Regeneron Pharmaceuticals
Accepted 2023-01-30 00:00:00 ET · period of report 2023-01-27 · accession 0001883850-23-000027 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2023-01-30 | 2023-01-27 | REGN | BROWN MICHAEL S | Dir | S - Sale+OE | $747.00 | -1 | 1,247 | -0.1% | -$747 |
| D | 2023-01-30 | 2023-01-27 | REGN | BROWN MICHAEL S | Dir | M - OptEx | $520.01 | +1 | 1,248 | +0.1% | +$520.01 |
| D | 2023-01-30 | 2023-01-27 | REGN | BROWN MICHAEL S | Dir | M - OptEx | $0.00 | -1 | 6,141 | -0.0% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-01-27 | S | D | 1 | $747.00 | 1,247 | D | — | — | |
| 2 | Common | Common Stock | 2023-01-27 | M | A | 1 | $520.01 | 1,248 | D | — | — | |
| 3 | Derivative | Non-Qualified Stock Option (right to buy) | 2023-01-27 | M | D | 1 | $0.00 | 6,141 | D | $520.01 · — to 2026-01-04 | 1 Common Stock | (F3) The stock option becomes exercisable in three equal annual installments, commencing one year after the date of grant. |